- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy, conventional surgery
- Biological · Procedure
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 1
- States / cities
- Newport Beach, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 5,164
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- MK-0752
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 12
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 9 more
- Conditions
- Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Acute Lymphoblastic Leukemia, Neurofibromatosis Type 1
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 35 Years
- Enrollment
- 1,720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Prednisone, Therapeutic Immune Globulin
- Other · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 8 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2022
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 78 more
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
- Interventions
- Pharmacological Study, Romidepsin
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 11
- States / cities
- Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more
- Conditions
- Basal Cell Carcinoma, Melanoma, Squamous Cell Carcinoma, Non-Malignant Skin Disorders
- Interventions
- confocal microscopy in vivo
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 4
- States / cities
- Basking Ridge, New Jersey • Harrison, New York • Hauppauge, New York + 1 more
- Conditions
- Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma, Metastatic Sinonasal Adenocarcinoma, Locally Advanced Sinonasal Adenocarcinoma, Metastatic Large-cell Neuroendocrine Carcinoma, Locally Advanced Large-cell Neuroendocrine Carcinoma, Metastatic Olfactory Neuroblastoma, Locally Advanced Olfactory Neuroblastoma, Metastatic Sinonasal Undifferentiated Carcinoma, Locally Advanced Sinonasal Undifferentiated Carcinoma
- Interventions
- Enasidenib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- gene expression analysis, microarray analysis, polymorphism analysis, proteomic profiling, flow cytometry, immunologic technique, laboratory biomarker analysis, biopsy
- Genetic · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
- Interventions
- IPN01194
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • New Haven, Connecticut + 2 more
- Conditions
- Glioblastoma, Glioblastoma (GBM), Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Gliosarcoma, Adult, Gliosarcoma of Brain
- Interventions
- C134
- Drug
- Lead sponsor
- James Markert, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
- Interventions
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Drug · Combination Product
- Lead sponsor
- Marengo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Sacramento, California • Celebration, Florida • Miami, Florida + 10 more
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Melanoma, Stage II, Melanoma Stage IV
- Interventions
- Assessment, Biospecimen Collection, Quality-of-Life Assessment, Questionnaire Administration
- Behavioral · Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
- Interventions
- KIN-2787, KIN-2787 and binimetinib
- Drug
- Lead sponsor
- Pierre Fabre Medicament
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 11 more
- Conditions
- Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
- Interventions
- Pembrolizumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Intracranial Neoplasms, Neoplasms, Brain, Neoplasms, Intracranial, Primary Brain Neoplasms, Primary Malignant Brain Neoplasms, Primary Malignant Brain Tumors, Gliomas, Glioblastoma
- Interventions
- 5-ALA (Gliolan)
- Drug
- Lead sponsor
- Constantinos Hadjipanayis
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Ann Arbor, Michigan • Detroit, Michigan + 1 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- adjuvant therapy, iodine I 125
- Procedure · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Epilepsy, Temporal Lobe, Temporal Lobe
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glioma, Glioblastoma, Brain Tumor, Recurrent
- Interventions
- ANG1005, Bevacizumab
- Drug
- Lead sponsor
- Angiochem Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 12
- States / cities
- La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- irinotecan hydrochloride, temozolomide
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer
- Interventions
- Not listed
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Melanoma, BRAF Gene Mutation
- Interventions
- Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib, Trametinib
- Drug
- Lead sponsor
- West Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Germantown, Tennessee
- Conditions
- Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
- Interventions
- Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
- Drug · Other
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 6 Years to 28 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Complete Hydatidiform Mole, Non-Metastatic Gestational Trophoblastic Tumor, Partial Hydatidiform Mole
- Interventions
- Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Other · Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 28
- States / cities
- Mountain View, California • Palo Alto, California • San Francisco, California + 21 more
- Conditions
- Retinoblastoma, Retinal Neoplasm
- Interventions
- Enucleation, Vincristine, Carboplatin, Focal Therapies, External Beam Radiation, Vincristine and Topotecan, Vincristine + Carboplatin + Etoposide, vincristine, cyclophosphamide, and doxorubicin, Vincristine, Carboplatin and Etoposide, Periocular carboplatin, G-CSF
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2024
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee